Aileron Therapeutics, Inc. (NASDAQ:ALRN) Sees Large Drop in Short Interest

Aileron Therapeutics, Inc. (NASDAQ:ALRN) was the recipient of a large decrease in short interest in the month of October. As of October 31st, there was short interest totalling 233,300 shares, a decrease of 8.7% from the October 15th total of 255,600 shares. Currently, 1.2% of the company’s stock are short sold. Based on an average daily volume of 74,800 shares, the short-interest ratio is presently 3.1 days.

Aileron Therapeutics Trading Down 13.3 %

ALRN stock opened at $2.87 on Monday. The stock has a 50-day moving average price of $3.48 and a two-hundred day moving average price of $3.13. Aileron Therapeutics has a 1 year low of $1.57 and a 1 year high of $7.42. The stock has a market cap of $62.18 million, a PE ratio of -0.92 and a beta of 2.35.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Geode Capital Management LLC lifted its stake in Aileron Therapeutics by 34.8% in the 3rd quarter. Geode Capital Management LLC now owns 229,817 shares of the company’s stock valued at $814,000 after acquiring an additional 59,370 shares in the last quarter. Sigma Planning Corp raised its holdings in shares of Aileron Therapeutics by 68.3% in the third quarter. Sigma Planning Corp now owns 212,410 shares of the company’s stock valued at $752,000 after purchasing an additional 86,185 shares during the last quarter. KG&L Capital Management LLC bought a new stake in shares of Aileron Therapeutics in the third quarter worth $46,000. University of Texas Texas AM Investment Management Co. acquired a new position in Aileron Therapeutics during the second quarter worth $4,925,000. Finally, Nantahala Capital Management LLC grew its position in Aileron Therapeutics by 82.1% in the second quarter. Nantahala Capital Management LLC now owns 464,367 shares of the company’s stock valued at $1,286,000 after purchasing an additional 209,367 shares in the last quarter. 90.89% of the stock is currently owned by institutional investors.

About Aileron Therapeutics

Aileron Therapeutics, Inc, a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).